Markets

Auris Medical slashes proposed price to $6, increases insider buying; market cap drops 40%

An image of a pen, calculator and papers
Credit: Shutterstock photo

Auris Medical, a biotech developing treatments for tinnitus and other inner ear disorders, lowered the proposed deal size for its upcoming IPO on Tuesday. The Zug, Switzerland-based company now plans to raise $56 million by offering 9.4 million shares at a price of $6 per share.

The company had previously filed to offer 6.9 million shares at a range of $10 to $12. At the midpoint of the revised range, Auris will raise 26% less in proceeds than previously anticipated. Its proposed market cap dropped 40% to $170 million.

Auris Medical, which was founded in 2003, plans to list on the NASDAQ under the symbol EARS. Jefferies and Leerink Partners are the joint bookrunners on the deal. It is expected to price tonight.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CYTO

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More